Otonomy is a biopharmaceutical company based in San Diego focused on developing therapeutics for diseases and disorders of the ear. It employs a proprietary technology to deliver drugs to the middle and inner ear via a single intratympanic injection. The company’s pipeline includes three product candidates: OTO-201 (an antibiotic in Phase 3 for pediatric middle ear effusion at the time of tympanostomy tube placement), OTO-104 (a steroid in the first of two pivotal studies for Meniere’s disease), and OTO-311 (an NMDA receptor antagonist in development for tinnitus). Otonomy secured $49M in Series D financing to advance these programs. The proceeds are intended to support a potential regulatory filing for OTO-201, completion of the ongoing pivotal OTO-104 study, and advancement of OTO-311 into clinical development. The company is led by president and CEO David A. Weber, Ph.D. Otonomy is a San Diego, CA–based clinical-stage biopharmaceutical company developing therapeutics for diseases and disorders of the inner and middle ear using proprietary technology. The company is led by president and CEO David A. Weber, Ph.D. It has two product candidates in clinical development: OTO-104, a steroid that completed a Phase 1b trial in Meniere’s disease patients, and OTO-201, an antibiotic that completed a Phase 1b trial in pediatric patients with middle ear effusion at the time of tympanostomy tube placement. Otonomy plans to use recent financing to fund late-stage clinical trials for OTO-201 and OTO-104 and to advance a third program toward clinical trials. The company also intends to use proceeds for general corporate purposes. To date, Otonomy has raised $94.4M. Otonomy is a San Diego-based clinical-stage biopharmaceutical company focused on locally delivered drug therapies for disorders of the inner and middle ear. Its lead candidate, OTO-104, is a sustained-release steroid in a Phase 1b trial for Meniere’s disease. The company is also developing OTO-203, a combination product for otitis media expected to enter clinical trials in 2011. Other pipeline candidates target acute and chronic hearing loss, balance disorders, and tinnitus. The new capital is intended to support the company’s first two programs through pivotal clinical studies and to expand its locally delivered ear drug pipeline. The company has previously completed a $10m Series A in June 2010 with Avalon Ventures, which also participated in the latest round. Otonomy is a San Diego, CA–based clinical-stage biopharmaceutical company developing sustained-release formulations for delivery of drugs to the inner and middle ear via a single intratympanic (IT) injection. Its core technology is a sustained-release formulation designed for optimal delivery from one IT injection. The company has advanced two products into active development: OTO-104, a sustained-release formulation of dexamethasone, and OTO-203, a sustained-release antibiotic for otitis media. A clinical trial of OTO-104 has been initiated in Meniere’s disease patients, with future studies planned for acute hearing loss. Preclinical studies reportedly showed prolonged, dose-proportional exposure of dexamethasone to the inner ear and acceptable tolerability in safety evaluations. The $10M Series A will support the ongoing OTO-104 trial, initiate IND-enabling studies for OTO-203, and continue early-stage development of a third program. Management indicated the financing will provide a foundation to raise additional capital from investors interested in treatments for hearing and balance disorders.

Total raised

$143M

Funding rounds

4

Latest round

Series D

Latest activity

Apr 2014